Athena Heart 310 Apr 2026

Mean reductions of ~49%, with peak effects reaching 87% .

(often associated with ATHENA trial contexts in heart disease research) is an experimental in vivo CRISPR gene-editing therapy designed to provide a one-time treatment for cardiovascular disease risk factors. It specifically targets the ANGPTL3 gene in the liver to permanently lower high levels of triglycerides (TG) and "bad" LDL cholesterol. 💡 Key Trial Results (Phase 1) ATHENA HEART 310

The treatment has been generally well-tolerated, with minor side effects like back pain or nausea reported during infusion. 🧬 Mechanism and Targets Mean reductions of ~49%, with peak effects reaching 87%

Detailed clinical summaries and press releases are available directly from CRISPR Therapeutics and medical news sources like Drug Discovery News . If you'd like to dive deeper into the research: Mean reductions of ~49%